A Phase 1/2 interventional study of Autologous CD5 CAR T-cells and Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells in T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse and Refractory Acute Lymphoblastic Leukemia, sponsored by Beijing GoBroad Hospital. Recruiting at 4 sites in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Beijing GoBroad Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 27 open to participants now, 28 under way, 4 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China.
Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 12th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 11 of the 27 other live ones, and was the 46th registered.
421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.
Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →27 of the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:
Beijing Biotech · Sites in China
Ages 18–75
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–75
yuejun Liu · Sites in China
Ages 14+
Chongqing Precision Biotech Co., Ltd · Sites in China
Ages 18–75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1 mo–18 yrs
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.
This study: 1 Year to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 20 · Phase 3 5 · Phase 4 1
First in 2016; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is above the median of 30 across 323 interventional studies indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 30 across the 50 interventional studies, 207 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 51 have an industry lead sponsor. The 10 most frequent:
Beijing GoBroad Hospital is the lead sponsor of 35 studies on the registry; 35 are open to participants now.
Beijing GoBroad Hospital has 3 studies filed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
11 of the studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07541755Phase 3Fujian Medical University Union HospitalPD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL | 2027-01-31 |
| NCT05376111The First Affiliated Hospital of Soochow UniversityStudy of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | 2026-12-01 |
| NCT06874946Peking University People's HospitalNanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL | 2026-12-31 |
| NCT07070323Beijing GoBroad HospitalA Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies | 2026-12-31 |
| NCT07523555Beijing BiotechAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | 2027-03-14 |
Add all 11 to your calendar (.ics) → With an account.
Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from starting dose level 1: 1×10\^6 (±20%) to dose level 2: 2×10\^6 (±20%) in three cohorts (autologous, previous-transplant-donor or newly matched donor-derived CD5 CAR T cells). If the manufactured cells are not sufficient to meet the preassigned standard dose criteria, patients will be given infusion at a low dose level of 5×10\^5 (±20%) /kg. The primary objective is to evaluate the safety and tolerability of CD5 CAR T cell therapy in subjects, determine the OBD and recommend phase 2 dose (RP2D) in phase 1, and evaluate the efficacy of CD5 CAR T cell therapy in phase 2. The primary endpoint is the type and incidence of dose-limiting toxicity (DLT) within 28 days, and the incidence and severity of adverse events (AEs) within 30 days after CD5 CAR T-cell infusion in phase 1, the best overall response (BOR) at 3 months (± 1 week) after CD5 CAR T-cell infusion in phase 2. A total number of 54 subjects will be enrolled.
详细描述
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Only patients who meet all the following criteria can be included:
1. Candidates with relapse or CD5+ T-cell , who have progressed after treatment with all standard therapies or been intolerant of standard care, have limited prognosis with currently available therapies and have no available curative treatment options (such as stem-cell transplantation (SCT) or chemotherapy); 2. For subjects who received autologous CD5 CAR T cells, the tumor burden in peripheral blood is less than 20%, and suspending anti-neoplastic treatment for more than 2 weeks; 3. Aged 1-70 years; 4. No severe allergy; 5. (ECOG) performance status 1 score 0 to 2; 6. Patients are expected to live for at least 60 days; 7. CD5+ on blasts in bone marrow (BM) or cerebrospinal fluid (CSF) and tumor tissues by flow cytometry and immunohistochemistry, respectively. (Positive rate >80% by flow cytometry with less than one log difference in mean fluorescence intensity from normal T cells, or positive rate >30% positive by immunohistochemistry); 8. Provide a signed before any screening procedure. Subjects who voluntarily participate in the study should have the ability to understand and sign the informed consent form and be willing to follow the study visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Children candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form and their legal guardian or patient advocate has also need to sign the treatment consent form and voluntary consent form, respectively. Children candidates of 1-7 can be recruited after the legal guardian or patient advocate has signed the treatment consent form and voluntary consent form; 9. Have available hematopoietic stem cell transplantation donor for the subject who received newly matched donor-derived CD5 CAR T cells, and is willing to perform SCT when CR is achieved.
-
Exclusion Criteria:
Patients with at least one of the following conditions are excluded:
1. Impaired consciousness or intracranial hypertension; 2. Symptomatic congestive heart failure or severe cardiac arrhythmia; 3. Manifestations of severe respiratory system failure; 4. Co-existence with other ; 5. Disseminated intravascular coagulation; 6. Serum creatinine and/or blood urea nitrogen (BUN) ≥ 1.5-fold upper limit; 7. Sepsis or other uncontrollable infections; 8. Uncontrollable diabetes; 9. Serious mental illness; 10. Apparent and active intracranial lesions on cranial magnetic resonance imaging (MRI); 11. Underwent organ transplantation, excepting SCT; 12. Pregnant females; 13. Positive test for infectious hepatitis, acquired immune deficiency syndrome (AIDS) or syphilis; 14. Post-CAR SCT is not feasible in patients who plan to receive newly matched donor-derived CD5 CAR T cells; 15. Inability to collect peripheral blood mononuclear cells (PBMC) or no frozen PBMC available for CAR T cell manufacturing.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a lymphodepleting regimen, the patients will receive autologous CD5 CAR T-cell infusion.
Drug: Autologous CD5 CAR T-cells
After a lymphodepleting regimen, the patients will receive prior SCT donor-derived CD5 CAR T-cell infusion.
Drug: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells
After a lymphodepleting regimen, the patients will receive newly matched donor-derived CD5 CAR T-cell infusion
Drug: Newly matched donor-derived CD5 CAR T-cells
Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
Phase 1-The incidence and type of dose-limiting toxicity (DLT)
The number of patients experiencing dose-limiting toxicity (DLT) will be evaluated and the type of DLT will be recorded.
Time frame: 28 days after CD5 CAR T cell infusion
Phase 1-The incidence and severity of adverse events (AEs)
The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.
Time frame: 30 days after CD5 CAR T cell infusion
Phase 2-Antitumor effect
Assessment of best overall response (BOR) rate. BOR rate is the percentage of patients with the best overall response in complete response (CR), complete response with incomplete hematological recovery (CRi) or partial response (PR) based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
Time frame: 3 months (± 1 week) after CD5 CAR T infusion
Phase 1-Objective response rate (ORR)
Objective response rate (ORR) is the percentage of subjects who have achieved CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
Time frame: 30 days after CD5 CAR T cell infusion
Phase 1-Pharmacokinetics of CD5 CAR T cells
The proliferation and survival of CAR T cells will be measured by flow cytometry and quantitative polymerase chain reaction (qPCR).
Time frame: Up to 2 years after CD5 CAR T cell infusion
Phase 1-The incidence and severity of adverse events (AEs).
The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.
Time frame: From 30 days to 2 years after CD5 CAR T cell infusion
Phase 1-Best overall response (BOR) rate.
BOR rate is the percentage of patients with the best overall response in CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
Time frame: 3 months (± 1 week) after CD5 CAR T cell infusion
Phase 2-Objective response rate (ORR)
Objective response rate (ORR) is the percentage of subjects who have achieved CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.
Time frame: 1 months and 3 months after CD5 CAR T cell infusion
Phase 2- The incidence and severity of AEs
The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.
Time frame: Up to 2 years
Phase 2- Progression free survival (PFS)
Progression-free survival (PFS) is defined as the time from the initial CD5 CAR T cell infusion to the date of progression or death for any cause.
Time frame: Up to 2 years
Phase 2- Overall survival (OS).
Overall survival (OS) is defined the time from the initial CD5 CAR T cell infusion to death for any cause.
Time frame: Up to 2 years
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma →
Beijing GoBroad Hospital